Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Regulatory review of drugs and devices: Early scientific advice to manufacturers - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 256137
Later capture
Regulatory review of drugs and devices: Early scientific advice to manufacturers - Canada.ca
Jan 2, 2026
hc-20260101
ID 428610
updated2 sections changed
2 sections changed0 added0 removed+0 / -3 linesChange ratio: 7%
--- +++ @@ -1,6 +1,4 @@ Early scientific advice to manufacturers-From:-Health Canada This project will result in Health Canada and Health Technology Assessment (HTA) organizations working together. This will allow them to give scientific advice to manufacturers at the same time early in the drug development process. Patient involvement will be an important part of the process. At this time, Health Canada and Canadian HTA organizations work independently to give scientific advice to drug manufacturers. Once a drug is developed, Health Canada must give an authorization before the drug can be marketed. After market authorization the HTA organizations give drug funding recommendations to:@@ -18,5 +16,4 @@ developing a guidance document for consultation in 2019 We expect that all parts of this project will be fully in place by spring 2020. Page details-Date modified: 2018-02-16